Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FATP1-IN-2, an arylpiperazine derivative, serves as an orally active inhibitor of the fatty acid transport protein 1 (FATP1) with potency in humans (IC50=0.43 μM) and mice (IC50=0.39 μM).
Description | FATP1-IN-2, an arylpiperazine derivative, serves as an orally active inhibitor of the fatty acid transport protein 1 (FATP1) with potency in humans (IC50=0.43 μM) and mice (IC50=0.39 μM). |
Targets&IC50 | FATP1 (mouse):0.39 μM (IC50), FATP1 (human):0.43 μM (IC50) |
In vivo | FATP1-IN-2 administered orally at a dosage of 10 mg/kg achieves a maximum concentration (C max) surpassing the IC 50 value in mice[1]. Additionally, across dosages of 3, 10, and 30 mg/kg over a period of four weeks, FATP1-IN-2 does not alter triglyceride (TG) content in any tissue at any administered dose[1]. This implies stable triglyceride levels across varying dosages during the evaluation period in the mouse model. |
Synonyms | FATP1-IN-2 |
Molecular Weight | 353.401 |
Formula | C19H20FN5O |
CAS No. | 2650944-83-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FATP1-IN-2 2650944-83-3 FATP1IN2 FATP1 IN 2 FATP-1-IN-2 inhibitor inhibit